Extent of the low-density line is associated with time to fracture in children with congenital anterolateral bowing of the tibia: a retrospective survival analysis - Top-Institutions - MDSpire

Extent of the low-density line is associated with time to fracture in children with congenital anterolateral bowing of the tibia: a retrospective survival analysis

  • By

  • Jiaqi Tian

  • Ge Yang

  • Yonghong Xie

  • Le Xu

  • Lan Yin

  • Yaqi Ouyang

  • Yinzhi Yi

  • Jianhui Xie

  • June 15, 2026

  • 0 min

Share

Top Institutions in Orthopedic Medicine

Brief introduction explaining scope and methodology.

  • #1

    Hunan Children's Hospital
    Hunan Children's Hospital

    Changsha, Hunan

    Key Differentiators

    • Pediatric Orthopedics

  • #2

    Oulu University Hospital
    Oulu University Hospital

    Oulu, Oulu

    Key Differentiators

    • Pediatric Orthopedics

  • #3

    Lianyungang 2nd People’s Hospital
    Lianyungang 2nd People’s Hospital

    Lianyungang, Jiangsu

    Key Differentiators

    • Pediatric Orthopedics

  • #4

    University of Münster
    University of Münster

    Münster, North Rhine-Westphalia

    Key Differentiators

    • Pediatric Orthopedics

  • #5

    Paediatric Orthopaedic Unit
    Paediatric Orthopaedic Unit

    Unknown, Unknown

    Key Differentiators

    • Pediatric Orthopedics

Original Source(s)

Extent of the low-density line is associated with time to fracture in children with congenital anterolateral bowing of the tibia: a retrospective survival analysis

  • by Jiaqi Tian, Ge Yang, Yonghong Xie, Le Xu, Lan Yin, Yaqi Ouyang, Yinzhi Yi, Jianhui Xie

  • June 15, 2026

Related Content

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Distribution and associated factors of neck and shoulder pain among primary school children in Shijiazhuang city, Hebei province, China

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min